5/2
08:00 am
incy
Incyte to Present at Upcoming Investor Conference
Low
Report
Incyte to Present at Upcoming Investor Conference
5/1
02:04 pm
incy
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at TD Cowen from $88.00 to $80.00. They now have a "buy" rating on the stock.
Low
Report
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at TD Cowen from $88.00 to $80.00. They now have a "buy" rating on the stock.
5/1
11:25 am
incy
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/1
08:53 am
incy
Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $83.00 price target on the stock, down previously from $84.00.
Low
Report
Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $83.00 price target on the stock, down previously from $84.00.
5/1
08:36 am
incy
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at BMO Capital Markets from $56.00 to $52.00. They now have a "market perform" rating on the stock.
Low
Report
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at BMO Capital Markets from $56.00 to $52.00. They now have a "market perform" rating on the stock.
4/30
01:31 pm
incy
Incyte misses quarterly profit on weak sales of lead drug [Reuters]
Low
Report
Incyte misses quarterly profit on weak sales of lead drug [Reuters]
4/30
01:17 pm
incy
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
Low
Report
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
4/30
10:20 am
incy
Incyte misses quarterly profit on weak sales of lead drug [Yahoo! Finance]
Low
Report
Incyte misses quarterly profit on weak sales of lead drug [Yahoo! Finance]
4/30
07:22 am
incy
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs [Yahoo! Finance]
Low
Report
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs [Yahoo! Finance]
4/30
07:00 am
incy
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Low
Report
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
4/26
04:31 pm
incy
Repare Therapeutics appoints Steven Stein to its board of directors [Seeking Alpha]
Low
Report
Repare Therapeutics appoints Steven Stein to its board of directors [Seeking Alpha]
4/26
04:15 pm
incy
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors [Yahoo! Finance]
Low
Report
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors [Yahoo! Finance]
4/26
01:55 pm
incy
Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade) [Seeking Alpha]
Low
Report
Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade) [Seeking Alpha]
4/25
03:44 pm
incy
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX [Yahoo! Finance]
Low
Report
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX [Yahoo! Finance]
4/24
08:10 am
incy
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $92.00 to $84.00. They now have an "outperform" rating on the stock.
Low
Report
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $92.00 to $84.00. They now have an "outperform" rating on the stock.
4/23
11:08 am
incy
Incyte (INCY) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]
Low
Report
Incyte (INCY) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]
4/23
07:38 am
incy
Incyte to acquire immune-focused drug developer Escient [Seeking Alpha]
Low
Report
Incyte to acquire immune-focused drug developer Escient [Seeking Alpha]
4/23
07:04 am
incy
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists [Yahoo! Finance]
Low
Report
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists [Yahoo! Finance]
4/23
07:02 am
incy
Incyte Co. (NASDAQ: INCY) is now covered by analysts at Cantor Fitzgerald. They set a "neutral" rating on the stock.
Low
Report
Incyte Co. (NASDAQ: INCY) is now covered by analysts at Cantor Fitzgerald. They set a "neutral" rating on the stock.
4/23
07:00 am
incy
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Low
Report
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
4/15
09:32 am
incy
The past three years for Incyte (NASDAQ:INCY) investors has not been profitable [Yahoo! Finance]
Low
Report
The past three years for Incyte (NASDAQ:INCY) investors has not been profitable [Yahoo! Finance]
4/11
08:00 am
incy
Incyte to Report First Quarter Financial Results
Low
Report
Incyte to Report First Quarter Financial Results
4/5
07:35 pm
incy
SEC Wins Trial in Novel ‘Shadow' Insider Trading Crackdown [BNN Bloomberg (Canada)]
Low
Report
SEC Wins Trial in Novel ‘Shadow' Insider Trading Crackdown [BNN Bloomberg (Canada)]
4/1
11:14 am
incy
Top 20 S&P 500 stocks by hedge fund net exposure - BofA [Seeking Alpha]
Low
Report
Top 20 S&P 500 stocks by hedge fund net exposure - BofA [Seeking Alpha]
4/1
09:44 am
incy
Incyte and CMS collaborate for povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and SEA [Seeking Alpha]
Low
Report
Incyte and CMS collaborate for povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and SEA [Seeking Alpha]